The drugmaker said the results for giredestrant open the door to adding a treatment option at an early stage of the cancer, ...

Roche's ROG.S experimental oral drug giredestrant has been shown to cut the risk of recurrence of a common form of breast ...

The partnership will expedite the availability of Freenome's tests in markets outside the U.S, according to the company.

Roche claimed the results make its drug giredestrant the first of its kind, a so-called oral SERD, to show a benefit in the ...

Roche has built the evidence for its oral BTK inhibitor fenebrutinib in multiple sclerosis (MS) with two phase 3 readouts ...

The nods allow Regeneron to better compete with Roche, which stormed the market in 2022 with Vabysmo. The Swiss drugmaker's ...

As Roche works to switch certain patients with breast cancer over to a fixed-dose combination of two medicines, its ...

Roche Holding AG said a multiple sclerosis drug showed it could work for most forms of the disease in two late-stage trials, ...

The drug appears effective against both “relapsing” and “primary progressive” forms of the disease, though some analysts ...

The approval puts Lunsumio on the same footing as Epkinly (epcoritamab) in FL – a form of non-Hodgkin lymphoma (NHL) – as ...